Business
Leeds drops SSI 78% over Mupirocin with Steriwave
Ondine Biomedical Inc. announced that a published Leeds study in The Journal of Laryngology & Otology demonstrates Steriwave® nasal photodisinfection reduced surgical site infections by 78% compared to standard mupirocin in high-risk endoscopic endonasal skull-base surgery, with a number needed to treat of 9 and a cost to prevent one SSI at only 12.3% of the average treatment cost. The study found a 3.2% SSI rate with Steriwave versus 14.6% with mupirocin, and importantly, no cases of meningitis occurred with Steriwave compared to 5 cases in the mupirocin group, suggesting significant cost savings and improved patient outcomes. Disclaimer*
About this update from Ondine Biomedical, Inc.
30 June 2026 ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine", or "the Company") Published Leeds Study Shows Steriwave® Reduced Surgical Site Infections by 78% versus standard of care using Mupirocin in High Risk Endoscopic Endonasal Skull-Base Surgery · Leeds researchers conclude in published study that Steriwave nasal photodisinfection be considered for routine adoption in high risk endoscopic endonasal skull-based surgeries, as data confirms significant reduction in surgical site infections (SSI) and meningitis risk over current standard of care using topical antibiotic mupirocin. · With a number needed to treat (NNT) of only 9, the cost to prevent one SSI is found to be only 12.3% of the average published cost to treat one SSI. Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies for the prevention and treatment of hospital infections, announces that full results from Leeds Teaching Hospitals' evaluation of Steriwave® nasal photodisinfection versus mupirocin in endoscopic anterior skull-base surgery have been published in The Journal of Laryngology & Otology. The Leeds researchers state that given its broad-spectrum rapid action, excellent compliance and lack of resistance potential, Steriwave represents a compelling alternative to mupirocin-based decolonisation and should be considered for routine adoption. The Leeds researchers, Dr Paul Nix (Dept. of Otolaryngology) and Drs. Atul Tyagi, Nick Phillips and Asim Sheikh (Dept. of Neurosurgery) conclude that Steriwave significantly reduces SSI, antibiotic usage and ENT outpatient burden following endoscopic anterior skull base surgery. With a relative risk reduction of 78%, the number needed to treat would be 9 patients (95% CI: 5 to 27). The study finds an approximate cost of £774 per SSI prevented which compares (at only 12.3%) favourable to the published estimates of £6,3001 average cost to treat a (non-meningitis) neurosurgery SSI and less than 2% of a meningitis related SSI.2 The publication entitled, 'Steriwave® a Non-Antibiotic Nasal Photodisinfection Strategy Reduces Infection Burden in Endoscopic Skull Base Surgery', reports findings from a single-centre, before-and-after service evaluation conducted at Leeds General Infirmary, of the Leeds Teaching Hospitals NHS Trust. The evaluation compared outcomes between 105 patients (52.5%) ...
View stock analysis, news, and events for Ondine Biomedical, Inc.